\u4e00\u793e\uff09\u65e5\u672c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5b66\u4f1a\u30cb\u30e5\u30fc\u30b9No.151\u3010\u5b66\u8853\u5831\u544a69\u3011<\/p>\n\n\n\n
\u6700\u8fd1\u306e\u8a71\u984c69\uff082021\/07\/13\u914d\u4fe1\uff09<\/p>\n\n\n\n
\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u4f75\u7528\u306b\u3088\u308b\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u304c\u3093\u6cbb\u7642\u306e\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u306e\u5897\u5f37<\/p>\n\n\n\n
Enhancement of abscopal effects on hyperthermic cancer therapy using an immune checkpoint blockade<\/p>\n\n\n\n
\u8fd1\u85e4\u3000\u9686, \u9f4b\u85e4\u6df3\u4e00\uff08\u5bcc\u5c71\u5927\u5b66\uff09,<\/p>\n\n\n\n
\u3000\u304c\u3093\u306e\u514d\u75ab\u6cbb\u7642\u304c\u6ce8\u76ee\u3055\u308c\u3066\u3044\u308b\u30022012\u5e74\u306e\u7dcf\u8aac\u3067\u306f\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u3088\u308b\u514d\u75ab\u7cfb\u306e\u8abf\u7bc0\u306b\u3064\u3044\u3066\u65b0\u65e7\u306e\u77e5\u898b\u304c\u8ff0\u3079\u3089\u308c\u3066\uff0c\u304c\u3093\u6cbb\u7642\u3068\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c*\u306b\u3064\u3044\u3066\u3082\u89e6\u308c\u3089\u308c\u3066\u3044\u308b1)\uff0e \u679c\u305f\u3057\u3066\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u6cbb\u7642\u306b\u304a\u3044\u3066\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3084\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u306e\u5bc4\u4e0e\u306f\u3069\u3046\u3067\u3042\u308d\u3046\u304b\uff1f<\/p>\n\n\n\n
\u3000\u3053\u3053\u3067\u306f\u5b9f\u9a13\u7528\u30e9\u30b8\u30aa\u6ce2\uff3bRF\uff3d8 MHz\u8a98\u96fb\u52a0\u6e29\u88c5\u7f6e\u306b\u3088\u308b\u5c40\u6240\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u52a0\u3048\u3066\u521d\u3081\u3066\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3067\u3042\u308bCTLA-4*\u6297\u4f53(C4)\u3092\u4f75\u7528\u3057\uff0c\u9060\u9694\u816b\u760d\u306b\u95a2\u3059\u308b\u5b9f\u9a13\u7684\u6297\u816b\u760d\u52b9\u679c\u3092\u8a55\u4fa1\u3057\u305f\u7814\u7a76\u5185\u5bb9\u306b\u3064\u3044\u3066\u7d39\u4ecb\u3059\u308b2)\uff0e\u30de\u30a6\u30b9\u4e73\u304c\u3093\u7d30\u80de\u682a4T1\u3092BALB\/cAJcl\u30de\u30a6\u30b9\u306e\u4e21\u811a\u306b\u79fb\u690d\u3057\u305f\u5f8c\uff0c\u4e00\u65b9\u306e\u816b\u760d\u306e\u307f\u306b\u5bfe\u3057\u3066\uff0cC4\u6295\u4e0e\u6cbb\u7642\uff0cRF\u52a0\u6e29\uff0842.5\u2103\uff0c20\u5206\u9593\uff09\u6cbb\u7642\uff0c\u304a\u3088\u3073\u4e21\u8005\u4f75\u7528\u6cbb\u7642\u304c\u5b9f\u65bd\u3055\u308c\u305f\uff0e\u6cbb\u7642\u816b\u760d\uff08HT\u816b\u760d\uff09\u304a\u3088\u3073\u9060\u9694\u975e\u6cbb\u7642\u816b\u760d\uff08UnHT\u816b\u760d\uff09\u306e\u816b\u760d\u5897\u6b96\u7387\u304a\u3088\u3073\u5168\u751f\u5b58\u7387\u304c\u8a55\u4fa1\u3055\u308c\u305f\uff0e\u307e\u305f\uff0c\u518d\u79fb\u690d\u751f\u7740\u7387\u304a\u3088\u3073\u8ee2\u79fb\u306b\u3064\u3044\u3066\u3082\u8abf\u3079\u3089\u308c\u305f.<\/p>\n\n\n\n
\u3000HT\u816b\u760d\u304a\u3088\u3073UnHT\u816b\u760d\u3068\u3082\u306b\uff0cC4\u6295\u4e0e\u5358\u72ec\u306b\u3088\u308a\u816b\u760d\u4f53\u7a4d\u306f\u308f\u305a\u304b\u306b\u4f4e\u4e0b\u3057\u305f\u304c\uff0c\u4f75\u7528\u7fa4\u3067\u306f\u9855\u8457\u306a\u816b\u760d\u4f53\u7a4d\u6291\u5236\u52b9\u679c\u304c\u8a8d\u3081\u3089\u308c\u305f\uff0e\u3055\u3089\u306b\uff0c\u4f75\u7528\u7fa4\u306728\u65e5\u76ee\u306e\u5b8c\u5168\u816b\u760d\u9000\u7e2e\u304c18\u5339\u4e2d7\u5339\u3067\u8a8d\u3081\u3089\u308c\u305f.\u4f75\u7528\u7fa4\u306fC4\u6295\u4e0e\u5358\u72ec\u7fa4\uff08\u6700\u9577\u751f\u5b58\u65e5\u657050\u65e5\uff09\u3068\u6bd4\u3079\u3066\u5168\u751f\u5b58\u7387\u3067\u3082\u6709\u610f\u306a\u9ad8\u5024\uff0880\u65e5\u5f8c\u306733\uff05\uff09\u3092\u793a\u3057\uff0c\u80ba\u3078\u306e\u8ee2\u79fb\u7387\u3082\u4f4e\u304b\u3063\u305f\uff0e\u307e\u305f\uff0c\u4f75\u7528\u7fa4\u3067\u5b8c\u5168\u816b\u760d\u9000\u7e2e\u3057\u305f\u30de\u30a6\u30b9\u306b\u816b\u760d\u3092\u518d\u79fb\u690d\u3057\u3066\u30825\u4f8b\u4e2d5\u4f8b\u304c\u751f\u5b58\u3057\u305f\uff0e\u3053\u308c\u3089\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u304a\u3088\u3073\u751f\u5b58\u7387\u5ef6\u9577\u52b9\u679c\u306b\u95a2\u3059\u308b\u5468\u8fba\u816b\u760d\u3078\u306e\u30ea\u30f3\u30d1\u7403\u30c8\u30e9\u30d5\u30a3\u30ad\u30f3\u30b0*\u306e\u5f79\u5272\u3092\u89e3\u660e\u3059\u308b\u305f\u3081\uff0c\u514d\u75ab\u6291\u5236\u5264FTY720*\u3092\u7528\u3044\u305f\uff0e\u305d\u306e\u7d50\u679c\uff0cHT\u816b\u760d\u3067\u306fFTY720\u306e\u5f71\u97ff\u306f\u306a\u304b\u3063\u305f\u304c\uff0cUnHT\u816b\u760d\u3067\u306f\u816b\u760d\u5897\u6b96\u9045\u5ef6\u52b9\u679c\u304c\u6d88\u5931\u3057\u305f\uff0e\u307e\u305f\uff0c28\u65e5\u76ee\u306e\u751f\u5b58\u7387\u3082FTY720\u6295\u4e0e\u306b\u3088\u308a92\uff05\u304b\u308925\uff05\u306b\u4f4e\u4e0b\u3057\u305f\uff0e\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u304c\u30ea\u30f3\u30d1\u7403\u30c8\u30e9\u30d5\u30a3\u30ad\u30f3\u30b0\u306b\u3088\u308b\u3053\u3068\u3092\u793a\u5506\u3059\u308b\u3082\u306e\u3067\u3042\u308b\uff0e\u4ee5\u4e0a\u3088\u308a\uff0c\u5c40\u6240\u52a0\u6e29\u4f75\u7528CTLA-4\u6297\u4f53\u6cbb\u7642\u306fHT\u816b\u760d\u3067\u306e\u6297\u816b\u760d\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b\u3070\u304b\u308a\u3067\u306a\u304f\uff0cUnHT\u816b\u760d\u3067\u3082\u540c\u69d8\u306e\u52b9\u679c\u3092\u793a\u3057\uff0c\u5168\u751f\u5b58\u7387\u3092\u5ef6\u9577\u306b\u5bc4\u4e0e\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\uff0e<\/p>\n\n\n\n
\u3000\u6700\u8fd1\uff0c\u591a\u767a\u8ee2\u79fb\u3092\u6709\u3059\u308b\u80de\u5de3\u578b\u6a2a\u7d0b\u7b4b\u8089\u816b\u306e\u75c7\u4f8b\u306b\u5bfe\u3057\uff0c\u4f4e\u7528\u91cf\u5316\u5b66\u7642\u6cd5\u3068\u5c40\u6240\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u4f75\u7528\u7642\u6cd5\u306b\u3088\u308a\uff0c\u52a0\u6e29\u9818\u57df\u306e\u307f\u306a\u3089\u305a\u9060\u9694\u8ee2\u79fb\u3082\u5b8c\u5168\u5bdb\u89e3\u3092\u793a\u3057\uff0c\u3053\u306e\u52b9\u679c\u306fNK\u7d30\u80de\u3084T\u7d30\u80de\u306e\u6d3b\u6027\u5316\u306b\u95a2\u9023\u3059\u308b\u3082\u306e\u3067\u3042\u3063\u305f\u3068\u3059\u308b\u81e8\u5e8a\u7d50\u679c\u304c\u767a\u8868\u3055\u308c\u305f3)\uff0e\u672c\u90a6\u3067\u30821998\u5e74\u306b\u3059\u3067\u306b\u6b63\u8377\u96fb\u30ea\u30dd\u30bd\u30fc\u30e0\u306b\u5c01\u5165\u3057\u305f\u78c1\u6027\u7c92\u5b50\u3092\u5909\u52d5\u78c1\u5834\u52a0\u6e29\u3059\u308b\u3053\u3068\u306b\u3088\u308a\uff0c\u975e\u52a0\u6e29\u816b\u760d\u306b\u304a\u3044\u3066\u3082\u5b8c\u5168\u9000\u7e2e\u3092\u793a\u3059\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u304c\u5831\u544a\u3055\u308c\uff0c\u3053\u308c\u306b\u306fCD8+\u304a\u3088\u3073CD4+T\u7d30\u80de\u3084\u816b\u760d\u9078\u629e\u7684\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de\u304c\u95a2\u4fc2\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f4)\uff0e\u8fd1\u5e74\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u5206\u91ce\u3067\u3082\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u4f75\u7528\u3082\u8003\u616e\u3055\u308c\u308b\u3088\u3046\u306b\u306a\u308a\u3001\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3092\u542b\u3081\u305f\u96c6\u5b66\u7684\u6cbb\u7642\u306b\u3088\u308a\u3001\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u306b\u3088\u308b\u975e\u6cbb\u7642\u304c\u3093\u90e8\u4f4d\u306e\u6cbb\u7642\u52b9\u679c\u304c\u671f\u5f85\u3055\u308c\u308b. \u4eca\u5f8c\uff0c\u65b0\u3057\u3044\u89b3\u70b9\u3067\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u306e\u6a5f\u5e8f\u306e\u89e3\u660e\u304c\u9032\u307f\uff0c\u304c\u3093\u6cbb\u7642\u6210\u7e3e\u306e\u5411\u4e0a\u306b\u5bc4\u4e0e\u3059\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u308b\uff0e<\/p>\n\n\n\n
\u53c2\u8003\u6587\u732e<\/p>\n\n\n\n
1) Frey B, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia, 28: 528-42, 2012.<\/p>\n\n\n\n
2) Ibuki Y, et al. Local hyperthermia combined with CTLA-4 blockade induces both local and abscopal effects in a murine breast cancer model. Int J Hyperthermia, 38: 363-71, 2021.<\/p>\n\n\n\n
3) Issels RD, et al. Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – A case report. Int J Hyperthermia, 37: 55-65, 2020.<\/p>\n\n\n\n
4) Yanase M, et al. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res, 89: 775\u201382, 1998.<\/p>\n\n\n\n
\u7528\u8a9e\u89e3\u8aac<\/p>\n\n\n\n
*\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\uff1a\u9060\u9694\u52b9\u679c, \u9060\u9054\u52b9\u679c\u3068\u79f0\u3059\u308b.\u301d\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u301f\u306e\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\uff08abscopal\uff09\u3068\u306f\uff0c\u30e9\u30c6\u30f3\u8a9e\u306e\u300c\u9060\u304f\u300d\u3068\u3044\u3046\u610f\u5473\u306e\u300c\u30a2\u30d6\u300d\u3068\u53e4\u4ee3\u30ae\u30ea\u30b7\u30a2\u8a9e\u306e\u300c\u72d9\u3046\u300d\u3068\u3044\u3046\u610f\u5473\u306e\u300c\u30b9\u30b3\u30d1\u30eb\u300d\u3092\u7d44\u307f\u5408\u308f\u305b\u305f\u8a00\u8449\uff0e\u4eca\u307e\u3067\u306f\u3042\u304f\u307e\u3067\u4e00\u90e8\u306e\u60a3\u8005\u3060\u3051\u3067\u898b\u3089\u308c\u308b\u73cd\u3057\u3044\u73fe\u8c61\u3068\u3055\u308c\u3066\u304d\u305f\u304c\uff0c\u305d\u308c\u3092\u9ad8\u7387\u3067\u767a\u751f\u3055\u305b\u308b\u30e1\u30ab\u30cb\u30ba\u30e0\u304c\u6b21\u7b2c\u306b\u660e\u3089\u304b\u306b\u306a\u308a\u3064\u3064\u3042\u308b\uff0e\u653e\u5c04\u7dda\u7167\u5c04\u3092\u53d7\u3051\u3066\u6b7b\u6ec5\u3042\u308b\u3044\u306f\u8106\u5f31\u5316\u3057\u305f\u304c\u3093\u7d30\u80de\u306f\uff0c\u514d\u75ab\u523a\u6fc0\u4f5c\u7528\u306e\u3042\u308b\u30bf\u30f3\u30d1\u30af\u8cea\u3084\u304c\u3093\u6297\u539f\u306a\u3069\u3092\u653e\u51fa\u3057\uff0c\u305d\u308c\u3092\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u3084\u6a39\u72b6\u7d30\u80de\u306a\u3069\u306e\u8840\u6db2\u4e2d\u306e\u6297\u539f\u63d0\u793a\u7d30\u80de\u304c\u51e6\u7406\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u7d30\u80de\u8868\u9762\u3078\u305d\u306e\u4e00\u90e8\u3092\u63d0\u793a\u3059\u308b\uff0e\u63d0\u793a\u3055\u308c\u305f\u6297\u539f\u306fT\u7d30\u80de\u53d7\u5bb9\u4f53\u3092\u4ecb\u3057\u3066 T\u7d30\u80de\u306b\u3088\u308a\u8a8d\u8b58\u3055\u308c\uff0cT\u7d30\u80de\u304c\u5206\u5316\u30fb\u6d3b\u6027\u5316\u3059\u308b\uff0e\u7d50\u679c\u3068\u3057\u3066\u816b\u760d\u7279\u7570\u7684\u7d30\u80de\u969c\u5bb3\u6027T\u30ea\u30f3\u30d1\u7403\uff08\u816b\u760d\u7279\u7570\u7684CTL\uff09\u304c\u6d3b\u6027\u5316\u3055\u308c\uff0c\u307e\u305f\uff0c\u7d30\u80de\u6027\u514d\u75ab\uff08\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u3084\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de\u306b\u3088\u308b\u76f4\u63a5\u653b\u6483\uff09\u53ca\u3073 \u6db2\u6027\u514d\u75ab\uff08B\u7d30\u80de\u3068\u6297\u4f53\u304c\u4e2d\u5fc3\u3068\u306a\u308b\u514d\u75ab\u53cd\u5fdc\uff09\u304c\u6d3b\u6027\u5316\u3055\u308c\u308b\uff0e\u305d\u308c\u304c\u4f53\u4e2d\u3092\u3081\u3050\u3063\u3066\uff0c\u653e\u5c04\u7dda\u3092\u7167\u5c04\u3057\u305f\u4ee5\u5916\u306e\u304c\u3093\u7d30\u80de\u3092\u898b\u3064\u3051\u3066\u653b\u6483\u3057\uff0c\u6cbb\u7642\u52b9\u679c\u306b\u8ca2\u732e\u3059\u308b\uff0e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u958b\u767a\u304a\u3088\u3073\u653e\u5c04\u7dda\u7167\u5c04\u6280\u8853\u306e\u9032\u6b69\u3067\u7dda\u91cf\u5897\u52a0\u304c\u53ef\u80fd\u3068\u306a\u308a\uff0c\u304c\u3093\u6cbb\u7642\u3078\u306e\u4f75\u7528\u52b9\u679c\u304c\u3042\u304d\u3089\u304b\u3068\u306a\u308a\uff0c\u6ce8\u76ee\u3055\u308c\u3066\u3044\u308b\uff0e<\/p>\n\n\n\n
*CTLA-4\uff1aCytotoxic T-lymphocyte-associated protein 4\uff0c\u5225\u540d:CD152\uff0e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u30fb\u30bf\u30f3\u30d1\u30af\u8cea\uff0e\u7d30\u80de\u50b7\u5bb3\u6027T\u30ea\u30f3\u30d1\u7403\u6297\u539f4\uff08CTLA-4\uff09\u306f\uff0c\u514d\u75ab\u5fdc\u7b54\u3092\u8ca0\u306b\u8abf\u7bc0\u3059\u308b\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u53d7\u5bb9\u4f53\u3067\uff0c\u3053\u306e\u963b\u5bb3\u306fT\u7d30\u80de\u3092\u76f4\u63a5\u6d3b\u6027\u5316\u3057\uff0c\u5236\u5fa1\u6027T\u7d30\u80de\uff08Treg\uff09\u306b\u3088\u308bT\u7d30\u80de\u6291\u5236\u3092\u89e3\u9664\u3057\uff0c\u9577\u671f\u306b\u308f\u305f\u308b\u6297\u816b\u760d\u52b9\u679c\u3092\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u304c\u3042\u308b\uff0e\u305d\u306e\u305f\u3081\uff0c\u6700\u9069\u306aCTLA-4\u963b\u5bb3\u7642\u6cd5\u306e\u7814\u7a76\u958b\u767a\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u308b\uff0e\u6297CTLA-4\u6297\u4f53\u306fCTLA-4\u3068\u6297\u539f\u63d0\u793a\u7d30\u80de\u4e0a\u306eB7\uff08CD80\/CD86\uff09\u3068\u306e\u7d50\u5408\u3092\u963b\u5bb3\u3059\u308b\u3053\u3068\u3067\uff0cT\u7d30\u80de\u4e0a\u306e\u5171\u523a\u6fc0\u5206\u5b50\u3067\u3042\u308bCD28\u3068B7\u306e\u7d50\u5408\u3092\u53ef\u80fd\u306b\u3057\uff0cT\u7d30\u80de\u3092\u518d\u6d3b\u6027\u5316\u3059\u308b\uff0e\u307e\u305f\uff0cTreg\u4e0a\u306eCTLA-4\u306b\u7d50\u5408\u3057\uff0cTreg\u306e\u514d\u75ab\u6291\u5236\u6a5f\u80fd\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3068\u3068\u3082\u306b\uff0cADCC\uff08Antibody-dependent-cellular-cytotoxicity\uff1a\u6297\u4f53\u4f9d\u5b58\u6027\u7d30\u80de\u50b7\u5bb3\uff09\u306b\u3088\u308a\u816b\u760d\u7d44\u7e54\u4e2d\u306eTreg\u3092\u6e1b\u5c11\u3055\u305b\u308b\u3053\u3068\u3067\u6297\u539f\u63d0\u793a\u7d30\u80de\u3092\u6210\u719f\u3055\u305b\u3066T\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3057\uff0cT\u7d30\u80de\u306e\u6297\u816b\u760d\u52b9\u679c\u3092\u4fc3\u9032\u3059\u308b\uff0eTremelimumab \u3084 Ipilimumab\u306a\u3069\u69d8\u3005\u306a\u304c\u3093\u306e\u305f\u3081\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u304c\u958b\u767a\u3055\u308c\u3066\u3044\u308b\uff0e<\/p>\n\n\n\n
*\u30ea\u30f3\u30d1\u7403\u306e\u30c8\u30e9\u30d5\u30a3\u30ad\u30f3\u30b0:\u30ea\u30f3\u30d1\u7403\u306e\u7d44\u7e54\u3078\u306e\u79fb\u52d5\u306e\u3053\u3068\u3092\u6307\u3059\uff0e\u30ea\u30f3\u30d1\u7403\u30db\u30fc\u30df\u30f3\u30b0\u304c\u3088\u304f\u4f7f\u308f\u308c\u308b\u304c\uff0c\u30db\u30fc\u30df\u30f3\u30b0\u306f\u7279\u306b\uff0c\u3042\u308b\u30ea\u30f3\u30d1\u7d44\u7e54\u304b\u3089\u5faa\u74b0\u3057\uff0c\u518d\u3073\u3082\u3068\u306e\u30ea\u30f3\u30d1\u7d44\u7e54\u306b\u623b\u3063\u3066\u304f\u308b\u3053\u3068\u3092\u6307\u3059\uff0e\u30ea\u30f3\u30d1\u7403\u306e\u30db\u30fc\u30e0\u306f\u80f8\u817a\uff0c\u9aa8\u9ac4\u306a\u3069\u3067\u3042\u308b\u304c\uff0c\u5927\u898f\u6a21\u306b\u307f\u3089\u308c\u308b\u30ea\u30f3\u30d1\u7403\u306e\u30c8\u30e9\u30d5\u30a3\u30ad\u30f3\u30b0\u306f\u8840\u6db2\u3068\u4e8c\u6b21\u30ea\u30f3\u30d1\u7d44\u7e54\u306e\u9593\u3067\u3042\u308a\uff0c\u3053\u308c\u306f\u751f\u307e\u308c\u305f\u5bb6\uff08\u30db\u30fc\u30e0\uff09\u306b\u623b\u308b\u73fe\u8c61\u3067\u306f\u306a\u3044\uff0e *FTY720\uff08Fingolimod\uff09\uff1a\u30d5\u30a3\u30f3\u30b4\u30ea\u30e2\u30c9\u306f\u514d\u75ab\u6291\u5236\u5264\u3067\uff0c\u30ea\u30f3\u30d1\u7403\u304c\u30ea\u30f3\u30d1\u7bc0\u304b\u3089\u4f53\u6db2\u4e2d\u306b\u51fa\u308b\u306e\u3092\u59a8\u3052\u3066\u672b\u68a2\u8840\u6db2\u4e2d\u306e\u30ea\u30f3\u30d1\u7403\uff08\u7279\u306b\uff0cT\u30ea\u30f3\u30d1\u7403\uff09\u306e\u6570\u3092\u4f4e\u4e0b\u3055\u305b\u3066\u514d\u75ab\u3092\u6291\u5236\u3059\u308b\uff0e\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u3067\u3042\u308b\u591a\u767a\u6027\u786c\u5316\u75c7\u6cbb\u7642\u85ac\u3068\u3057\u3066\u767a\u58f2\u3055\u308c\u3066\u3044\u308b\uff0e\u6f22\u65b9\u85ac\u306e\u51ac\u866b\u590f\u8349\u306e\u6d3b\u6027\u6210\u5206\u304b\u3089\u767a\u898b\u3055\u308c\uff0c\u30df\u30ea\u30aa\u30b7\u30f3\u306e\u8a98\u5c0e\u4f53\u3067\u3042\u308bFTY720\uff08Fingolimod\uff09\u304c\uff0c\u751f\u4f53\u5185\u3067SPHK-2 (Sphingosine kinase 2)\u306b\u3088\u308a\u30ea\u30f3\u9178\u5316\u3092\u53d7\u3051\u3066\u751f\u6210\u3057\u305fFTY720\u30ea\u30f3\u9178\u5316\u4f53\u306f\uff0cS1P2\u3092\u9664\u304f\u56db\u3064\u306eS1P(Sphingosine-1-phosphate)\u53d7\u5bb9\u4f53\u306b\u5bfe\u3057\u3066\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u3057\u3066\u50cd\u304f\uff0e\u7279\u306b\uff0cS1P1\u306b\u5bfe\u3057\u3066\u306f\uff0c\u3053\u306e\u53d7\u5bb9\u4f53\u306e\u5185\u5728\u5316\uff08\u30a8\u30f3\u30c9\u30b5\u30a4\u30c8\u30fc\u30b7\u30b9\uff09\u3092\u8a98\u5c0e\u3059\u308b\u7d50\u679c\uff0c\u4e0d\u6d3b\u6027\u5316\u3092\u62db\u304f\u6a5f\u80fd\u7684\u30a2\u30f3\u30bf\u30b4\u30cb\u30b9\u30c8\u3067\u3042\u308b\uff0e<\/p>\n","protected":false},"excerpt":{"rendered":"
\u4e00\u793e\uff09\u65e5\u672c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5b66\u4f1a\u30cb\u30e5\u30fc\u30b9No.151\u3010\u5b66\u8853\u5831\u544a69\u3011 \u6700\u8fd1\u306e\u8a71\u984c69\uff082021\/07\/13\u914d\u4fe1\uff09 \u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u4f75\u7528\u306b\u3088\u308b\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u304c\u3093\u6cbb\u7642\u306e\u30a2\u30d6\u30b9\u30b3\u30d1\u30eb\u52b9\u679c\u306e\u5897\u5f37 Enhancement […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"vkexunit_cta_each_option":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-1245","post","type-post","status-publish","format-standard","hentry","category-report"],"_links":{"self":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/1245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/comments?post=1245"}],"version-history":[{"count":1,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/1245\/revisions"}],"predecessor-version":[{"id":1246,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/1245\/revisions\/1246"}],"wp:attachment":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/media?parent=1245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/categories?post=1245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/tags?post=1245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}